reports
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 5, 2025, the Company granted 12 new employees 73,500 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such indivi...
Esperion Reports Second Quarter 2025 Financial Results and Provides Bu...
Esperion Reports Second Quarter 2025 Financial Results and Provides Business Update – Q2 2025 Total Revenue Grew 12% Y/Y to $82.4 Million – – Q2 2025 U.S. Net Product Revenue Grew 42% Y/Y to $40.3 Million – – Total Retail Prescription Equivalents Increased 10% from First Quarter – – Reached Settlement Agreements with Three ANDA Filers Not to Market Generic Versions of NEXLETOL® (bempedoic acid) Prior to 2040 – – First Quarter of Operating Income from Ongoing Business with Plans for Sustainable Profitability Starting in Q1 2026 – – Conference Call and Webcast Today at 8:00 a.m...
Esperion to Report Second Quarter 2025 Financial Results on August 5
Esperion to Report Second Quarter 2025 Financial Results on August 5 ANN ARBOR, Mich., July 22, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report second quarter 2025 financial results before the market opens on Tuesday, August 5, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and...
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Mar...
Esperion Reaches Settlement Agreement with Third ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., July 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Accord Healthcare Inc. This agreement resolves the patent litigation brought by Esperion against Accord Healthcare Inc. in response to Accord Healthcare Inc’s Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiration of the applicable patents....
Esperion Appoints Craig Thompson to Board of Directors
Esperion Appoints Craig Thompson to Board of Directors Brings More Than Twenty Years of Biopharmaceutical Leadership Experience ANN ARBOR, Mich., July 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it has appointed Craig Thompson, Chief Executive Officer of Cerevance, to its Board of Directors. Mr. Thompson will serve as an independent director. With Mr. Thompson’s appointment, Esperion’s Board of Directors now comprises eight members. “We are thrilled to welcome Craig to our Board of Directors. With more than two decades of biopharmaceutical industry leadership a...
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Ma...
Esperion Reaches Settlement Agreement with Second ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., June 02, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Hetero USA, Inc. and its affiliates Hetero Labs Limited, Hetero Labs Limited Unit-V, and Honour Lab Limited (together, Hetero USA). This agreement resolves the patent litigation brought by Esperion against Hetero USA in response to Hetero USA’ s Abbreviated New Drug Application (ANDA) seeking approval to...
Esperion to Participate in Upcoming June Investor Conferences
Esperion to Participate in Upcoming June Investor Conferences ANN ARBOR, Mich., May 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the following webcasted investor events during the month of June, which can be found on our investor relations . Jefferies Global Healthcare Conference in New York on June 4, 2025, at 1:25 p.m. ET. Goldman Sachs Global Healthcare Conference in Miami on June 9, 2025, at 10:40 a.m. ET. Live webcasts can be accessed on the investor and media section of the Esperion . Access to the webcast replay w...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Ge...
Esperion Reaches Settlement Agreement with ANDA Filer Not to Market Generic Version of NEXLETOL® (bempedoic acid) Prior to April 19, 2040 ANN ARBOR, Mich., May 12, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it has entered into a settlement agreement with Micro Labs USA, Inc. and its affiliate Micro Labs Limited (together, Micro Labs). This agreement resolves the patent litigation brought by Esperion against Micro Labs in response to Micro Labs’ Abbreviated New Drug Application (ANDA) seeking approval to market a generic version of NEXLETOL prior to the expiratio...
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Inv...
Esperion to Participate in H.C. Wainwright’s 3rd Annual BioConnect Investor Conference ANN ARBOR, Mich., May 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at 10 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperio...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)...
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on May 7, 2025, the Company granted 15 new employees 49,300 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual...
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (be...
Esperion Partners with HLS Therapeutics to Commercialize NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) in Canada – Esperion to Receive an Upfront Payment, Near-Term Milestones and Tiered Royalties on Product Sales – – Further Expands Global Access to Bempedoic Acid Products and Provides Opportunity to Bring Innovative Preventative Therapy to 2.6 million Canadians Living with Diagnosed Heart Disease – ANN ARBOR, Mich., May 08, 2025 (GLOBE NEWSWIRE) -- Esperion Therapeutics (NASDAQ: ESPR) today announced it has entered into a license and distribution agreement wi...
Esperion Reports First Quarter 2025 Financial Results
Esperion Reports First Quarter 2025 Financial Results – Q1 2025 Total Revenue of $65.0 Million, a Decrease of 53% Y/Y; Adjusting for One Time Milestone Received in Q1 2024, Total Revenue Grew 63% Y/Y – – Q1 2025 U.S. Net Product Revenue Grew 41% Y/Y to $34.9 Million – – Bempedoic Acid Earned Level 1a Recommendations in the 2025 ACC/AHA/ACEP/NAEMSP/SCAI Guideline for the Management of Patients with Acute Coronary Syndromes – – Expanded Development Portfolio with Introduction of Novel Program Targeting Primary Sclerosing Cholangitis (PSC) – – Conference Call and Webcast Today at 8:00 a.m....
Esperion to Participate in The Citizens Life Sciences Conference
Esperion to Participate in The Citizens Life Sciences Conference ANN ARBOR, Mich., April 25, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted Citizens Life Sciences Conference on May 8, 2025, at 12:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion TherapeuticsEsperion Therapeutics, Inc. ...
Esperion Unveils Promising Research Supporting Lead Development Candid...
Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025 – Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 202...
Esperion to Report First Quarter 2025 Financial Results on May 6
Esperion to Report First Quarter 2025 Financial Results on May 6 ANN ARBOR, Mich., April 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report first quarter 2025 financial results before the market opens on Tuesday, May 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after completion of the call and will b...
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovat...
Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 Highlighting Novel Insights into ATP Citrate Lyase (ACLY) Biology and its Therapeutic Potential in Multiple Life-Threatening Diseases ANN ARBOR, Mich., April 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that it will host an in-person R&D Day for analysts and investors on April 24, 2025, beginning at 9:00 a.m. ET in New York City. This event will feature presentations from company leadership and key opinion leaders to provide a deep dive int...
Esperion Appoints Robert E. Hoffman to Board of Directors
Esperion Appoints Robert E. Hoffman to Board of Directors - Veteran Industry Executive Brings Decades of Financial and Leadership Experience - ANN ARBOR, Mich., April 01, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of Robert E. Hoffman as an independent director, effective immediately, and he will also serve as Chairperson of the Audit Committee effective May 29, 2025. In addition, the Company announced that Nicole Vitullo and Antonio M. Gotto, Jr., M.D., D. Phil. will step down from the board of directors, effective June 1, 2025. “We are pleased to ...
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conf...
Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference ANN ARBOR, Mich., March 24, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will be participating in the webcasted 24th Annual Needham Virtual Healthcare Conference on April 7, 2025, at 8:45 a.m. ET. The live webcast can be accessed on the investor and media section of the Esperion . Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Esperion Therapeutic...
Esperion Aligns with U.S. Food and Drug Administration to Initiate Pha...
Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia – Confirms Sufficient Data to Complete Phase 2 Clinical Study Enrollment and Advance to Phase 3 Studies in Both Heterozygous and Homozygous Familial Hypercholesterolemia – – Establishes Pediatric Path Forward to Start and Complete Phase 3 Trial and Secure Additional Six-Month Patent Extension Through June 2031 – ANN ARBOR, Mich., March 20, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that f...
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results
Esperion Reports Fourth Quarter and Full Year 2024 Financial Results – FY24 Total Revenue Grew 186% Y/Y to $332.3 Million; FY24 U.S. Net Product Revenue Grew 48% Y/Y to $115.7 Million – –Q4 Total Revenue Grew 114% Y/Y to $69.1 Million; Q4 U.S. Net Product Revenue Grew 52% Y/Y to $31.6 Million – – Q4 Retail Prescription Equivalents Grew 45% Y/Y and 12% Q/Q – – Focused On Three Pillars for Building a Blockbuster Company: Continued Revenue Growth, Reaching Operating Profitability, and Portfolio Expansion/Pipeline Advancement – – Announces Development of Trip...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.